ZA88549B - Steroid 5-alpha-reductase inhibitors - Google Patents

Steroid 5-alpha-reductase inhibitors

Info

Publication number
ZA88549B
ZA88549B ZA880549A ZA88549A ZA88549B ZA 88549 B ZA88549 B ZA 88549B ZA 880549 A ZA880549 A ZA 880549A ZA 88549 A ZA88549 A ZA 88549A ZA 88549 B ZA88549 B ZA 88549B
Authority
ZA
South Africa
Prior art keywords
alpha
steroid
reductase inhibitors
double bond
reductase
Prior art date
Application number
ZA880549A
Other languages
English (en)
Inventor
Alan Holt Dennis
Alan Levy Mark
Walter Metcalf Brian
Original Assignee
Smithkline Beckman Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corporation filed Critical Smithkline Beckman Corporation
Publication of ZA88549B publication Critical patent/ZA88549B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ZA880549A 1987-01-28 1988-01-27 Steroid 5-alpha-reductase inhibitors ZA88549B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/007,539 US4888336A (en) 1987-01-28 1987-01-28 Steroid 5-alpha-reductase inhibitors

Publications (1)

Publication Number Publication Date
ZA88549B true ZA88549B (en) 1988-07-27

Family

ID=21726780

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA880549A ZA88549B (en) 1987-01-28 1988-01-27 Steroid 5-alpha-reductase inhibitors

Country Status (13)

Country Link
US (1) US4888336A (fr)
EP (1) EP0277002B1 (fr)
JP (1) JPS63192800A (fr)
AT (1) ATE77388T1 (fr)
AU (1) AU608560B2 (fr)
CA (1) CA1325006C (fr)
DE (1) DE3871965T2 (fr)
DK (4) DK37388A (fr)
ES (1) ES2042725T3 (fr)
GR (1) GR3005284T3 (fr)
IE (1) IE61594B1 (fr)
PT (1) PT86652B (fr)
ZA (1) ZA88549B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US4814324A (en) * 1987-03-06 1989-03-21 Merck & Co., Inc. Sterol inhibitors of testosterone 5α-reductase
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5405978A (en) * 1989-05-30 1995-04-11 The Upjohn Company Oxidative preparation of 3,5-secoandrost-5-one-3,17 β-dioic acid
CA2062792C (fr) * 1989-07-07 2006-03-21 Fernard Labrie Traitement des maladies liees aux androgenes
WO1991000731A1 (fr) * 1989-07-07 1991-01-24 Endorecherche Inc. Therapie combinee pour la prophylaxie et/ou le traitement de l'hyperplasie prostatique benigne
KR0181264B1 (ko) * 1989-07-07 1999-03-20 라브리 페르낭 성스테로이드 활성 억제용 안드로겐 유도체
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5250539A (en) * 1991-08-21 1993-10-05 Eli Lilly And Company Hexahydrobenzo[f]quinolinones
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CA2084799C (fr) 1991-12-17 2003-01-28 Glenn J. Gormley Methode de prevention du carcinome prostatique a l'aide de 17 beta-n-monosubstitue-carbamyl-4-aza-5 alpha-androst-1 -en-3-ones
EP0547687A1 (fr) * 1991-12-18 1993-06-23 Merck & Co. Inc. 17-bêta-substitués adamantyle/norbornanyle-4-aza-5-alpha-androsta-1-en-3-ones et androsta-3-ones
US5543406A (en) * 1991-12-20 1996-08-06 Glaxo Wellcome, Inc. Inhibitors of 5-α-testosterone reductase
HUT71484A (en) * 1992-05-20 1995-11-28 Merck & Co Inc Process for producing of 7beta-substituted-4-aza-5alpha-cholestan-ones as 5-alpha-reductase inhibitors and pharmaceuticals compositions containing them
US5610162A (en) * 1992-05-20 1997-03-11 Merck & Co., Inc. Ester derivatives of 4-aza-steroids
ES2148229T3 (es) * 1992-05-20 2000-10-16 Merck & Co Inc Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
WO1993023039A1 (fr) * 1992-05-20 1993-11-25 Merck & Co., Inc. 4-aza-5a-androstan ones substituees utilisees en tant qu'inhibitors de la 5a-reductase
JPH07508033A (ja) * 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド ５α−レダクターゼ阻害剤としての３−オキソ−４−アザステロイドの新規１７−エステル，アミド及びケトン誘導体
CA2135057A1 (fr) * 1992-05-20 1993-11-25 Bruce E. Witzel Inhibiteurs de la 4-azasteroide 5a-reductase a substituant sur le groupement amine en 17
WO1993023420A1 (fr) * 1992-05-20 1993-11-25 Merck & Co., Inc. NOUVEAUX 4-AZA-5α-ANDROSTANE-3-ONES SUBSTITUES EN POSITION 7β EN TANT QU'INHIBITEURS DE LA 5α-REDUCTASE
ES2149208T3 (es) * 1992-05-20 2000-11-01 Merck & Co Inc Inhibidores 4-azaesteroides de 5-alfa-reductasa.
ATE156839T1 (de) * 1992-05-20 1997-08-15 Merck & Co Inc Neue delta-17 und delta-20 ungesätigte und gesatigte 17--g(b)-substituierte-4-aza-5-g(a)- androstan-3-on verbindungen als inhibitoren von 5-alpha-reductase
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
HUT71514A (en) * 1992-05-21 1995-12-28 Endorecherche Inc Inhibitors of testosterone 5 alfa-reductase activity and pharmaceutical compositions containing the same
AU680818B2 (en) * 1992-05-21 1997-08-14 Endorecherche Inc. Improved antiandrogens
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994021614A1 (fr) * 1993-03-24 1994-09-29 Merck & Co., Inc. DERIVES DE 3-PHENANTHRIDINONES SUBSTITUES, UTILISES COMME INHIBITEURS DE LA 5α-REDUCTASE
WO1995000147A1 (fr) * 1993-06-28 1995-01-05 Merck & Co., Inc. INHIBITEURS DE L'ISOZYME 1 DE LA 4-AZA-PREGNANE 5α-REDUCTASE
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US6365597B1 (en) * 1996-02-14 2002-04-02 Aventis Pharmaceuticals Inc. 4-aza steroids
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
CA2330611A1 (fr) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Molecules bifonctionnelles et therapies basees sur celles-ci
SI1889198T1 (sl) 2005-04-28 2015-02-27 Proteus Digital Health, Inc. Farma-informacijski sistem
WO2007035716A2 (fr) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions de proteines rap specifiques des proteines contenant du cr, et leurs utilisations
DK2398500T3 (da) 2009-02-20 2019-05-13 2 Bbb Medicines B V Glutathion-baseret lægemiddelafgivelsessystem
SG175896A1 (en) 2009-05-06 2011-12-29 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897202A (en) * 1956-03-19 1959-07-28 Monsanto Chemicals 3-keto-4-aza-delta5-steroids and method of preparing same
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
ZA791752B (en) * 1978-04-13 1980-11-26 Merck & Co Inc 4-aza-17 beta -substituted-5 alpha -androstan-3-ones useful as 5 alpha -reductase inhibitors
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors

Also Published As

Publication number Publication date
DK169840B1 (da) 1995-03-13
AU1077888A (en) 1988-08-04
PT86652A (pt) 1988-02-01
DK169438B1 (da) 1994-10-31
EP0277002B1 (fr) 1992-06-17
CA1325006C (fr) 1993-12-07
IE61594B1 (en) 1994-11-16
DK37388A (da) 1988-07-29
IE880189L (en) 1988-07-28
EP0277002A2 (fr) 1988-08-03
GR3005284T3 (fr) 1993-05-24
DK37388D0 (da) 1988-01-26
DK73594A (da) 1994-06-21
DK168525B1 (da) 1994-04-11
ATE77388T1 (de) 1992-07-15
EP0277002A3 (en) 1988-10-26
US4888336A (en) 1989-12-19
DE3871965T2 (de) 1993-01-14
DE3871965D1 (de) 1992-07-23
DK196691A (da) 1991-12-05
PT86652B (pt) 1992-02-28
DK196691D0 (da) 1991-12-05
ES2042725T3 (es) 1993-12-16
JPS63192800A (ja) 1988-08-10
AU608560B2 (en) 1991-04-11

Similar Documents

Publication Publication Date Title
ZA88549B (en) Steroid 5-alpha-reductase inhibitors
GEP19981274B (en) Urinary follicle stimulating hormone, pharmaceutical composition, component of pharmaceutical composition
ZA899671B (en) Phosphinic acid substituted steroids as inhibitors of steroid 5-alpha-reductase
AU588202B2 (en) Dosage form for delivering acid sensitive beneficial agent
IL87885A (en) Pharmaceutical compositions having antiprogestational and anti-estrogenic activities for the treatment of hormone- dependent tumors
IL72928A (en) Bronchodilating pharmaceutical compositions containing 5,6-dialkoxybenzothiophene-2-carboxylic acid
EP0293751A3 (en) Taurohyodeoxycholic acid for the therapy of calculosis of the biliary tract and of biliary dyspepsia
AU2726088A (en) Ampule for controlled administration of beneficial agent
IL80900A (en) Pharmaceutical composition containing fibrinolytic compounds and carbacyclin analogues for treatment of thrombosis
NZ239022A (en) Piperidyl ethers and thioethers; preparatory processes and pharmaceutical compositions
ZA899670B (en) Phosphonic acid substituted steroids as steroid 5-alpha-reductase inhibitors
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
NZ223293A (en) Beta-alkyl melatonins and pharmaceutical compositions
NZ222434A (en) Tissue factor protein lacking its naturally associated phospholipid
ZA87332B (en) Compositions containing fixed combinations
AU7071487A (en) Chlorpheniramine therapy
PT83984A (en) Process for the preparation of novel 16,17-acetalsubstituted pregnane 21-oic derivatives and of pharmaceutical compositions containing the same
NZ228023A (en) 24(r)-scymnol; preparatory processes and pharmaceutical compositions
IL87320A (en) Polyhydro derivatives of 10,11-dihydro-5h-dibenzo-(a,d)cyclohepten-5,10-imine and pharmaceutical compositions containing them
EP0348664A3 (fr) Compositions pharmaceutiques contenant des monoacétoacétines pour le traitement des tumeurs
IL86731A (en) Pharmaceutical compositions containing estradien-3-one derivatives and androst-2-ene-carbonitrile derivatives
AU645042B2 (en) Use of a polypeptide having the activity of gamma interferon for the preparation of pharmaceutical compositions intended for the treatment of primary cancers of the pleura
IL85093A0 (en) Pharmaceutical compositions containing retinoids for the treatment of psychotic illnesses